FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912605890> ?p ?o ?g. }

• W2912605890 endingPage "1791" @default.
• W2912605890 startingPage "1791" @default.
• W2912605890 abstract "Abstract Myelofibrosis (MF) is caused by driver mutations which upregulate JAK/STAT signaling. The only curative treatment for MF is hematopoietic stem cell transplant. Ruxolitinib alleviates many of the symptoms in MF but does not significantly alter survival. There is, therefore, an urgent need for additional rational therapies for MF. Bone marrow fibrosis and collagen deposition are hallmarks of MF which have been attributed to megakaryocyte (MK) derived TGFβ, which also plays a role in myelo-proliferation. There are three isoforms of TGFβ (TGFβ1, β2, and β3). AVID200, which was constructed by fusing TGFβR ectodomains to IgG Fc regions, is a potent TGFβ trap with pM potency against two of the three TGFβ ligands, TGFβ1 and β3 (IC50 values of ~ 3 pM ). AVID200's IC50 for TGFβ2 is ~4,000-fold higher indicating that it has minimal activity against TGFβ2, which is desirable since TGFβ2 is a positive regulator of hematopoiesis. We explored the therapeutic potential of AVID200 by culturing MF or normal donor (ND) mononuclear cells (MNCs) first in the presence of stem cell factor and thrombopoietin (TPO) and then TPO alone in order to generate MK-enriched populations. Although the percentage of mature MKs from ND and MF MNCs was similar, the absolute number of CD41+/CD42+ MKs generated from MF MNCs was two-fold greater than ND MNCs. To determine the levels of TGFβ secreted by the MKs we screened MF and ND MNC conditioned media (CM). We observed significantly higher levels of TGFβ1 but not TGFβ2 and TGFβ3 in MF MK CM. The effects of AVID200 on MKs were then evaluated by measuring the levels of phosphorylated SMAD2. Treatment with 0.001 - 0.1 nM AVID200 decreased phosphorylation of SMAD2, suggesting that AVID200 blocks autocrine MK TGFβ signaling. The increased levels of TGFβ in MF patients promote the proliferation and deposition of collagen by mesenchymal stem cells (MSCs). Cellular proliferation of MSCs was evaluated following treatment with either recombinant TGFβ1 or ND/MF CM in the presence or absence of AVID200. In the absence of AVID200, both recombinant TGFβ1 and MK-derived CM increased the proliferation of MSCs by 1.4- and 1.6-fold respectively, which returned to basal levels with the addition of increasing concentrations of AVID200. These data indicate that AVID200 directly blocks the effect of TGFβ1 on MSCs. MF stroma is characterized by an increase in Type I collagen. We therefore examined if treatment with AVID200 interferes with the ability of TGFβ1 to induce collagen expression by MSCs. MSCs were cultured in presence of recombinant TGFβ1 alone or in combination with varying concentrations of AVID200 for 72 hours. Recombinant TGFβ1 alone induced an increase in COL1A1 mRNA expression as compared to untreated controls (p<0.01). Addition of AVID200 eliminated the TGFβ-mediated increase in COL1A1 expression in a dose dependent manner. ND and MF MK-derived CM also increased COL1A1 expression by MSCs as compared to un-treated controls (p<0.01) and that effect was eliminated by AVID200 treatment (p<0.01). We next demonstrated that TGFβ1 activated pSMAD2 in MSCs without affecting total SMAD2/3 expression and that SMAD2 phosphorylation was reduced by adding AVID200. Furthermore, AVID200 treatment decreased pSTAT3 which is associated with the ability of TGFβ to induce fibrosis. We next investigated the effect of AVID200 on MF hematopoiesis. Briefly, MNCs (which produce TGFβ) from two JAK2V617F+ MF patients were incubated with or without 50 nM of AVID200 and plated in semi-solid media. Treatment with AVID200 did not affect the overall number of colonies generated, but reduced the numbers of JAKV617F+ colonies while increasing the numbers of WT colonies: for PT1, there were 32% JAKV617F+ CFUs in untreated cultures (11 JAKV617F+/34 total colonies) versus 16% JAKV617F+ CFUs (7 JAKV617F+/42 total CFUs) in AVID200 treated cultures; for PT2 there were 100% JAKV617F+ CFUs in untreated cultures (37 JAKV617F+/37 total CFUs) versus 94% JAKV617F+ CFUs (49 JAK2V617F+/52 total CFUs) in AVID200 treated cultures. The in vivo effects of AVID200 on the development of MF in GATA1 low mice will be presented at the meeting. These data indicate that AVID200 selectively suppresses TGFβ1 signaling associated with the proliferation of MSCs and type I collagen synthesis, and depletes MF MNCs of JAK2V617F+progenitor cells. We conclude that AVID200 is a promising agent for treating MF patients which will be evaluated in a phase 1 clinical trial. Disclosures Mascarenhas: Novartis: Research Funding; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Roche: Research Funding; Janssen: Research Funding; Promedior: Research Funding; Merck: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding. Iancu-Rubin:Incyte: Research Funding; Merck: Research Funding; Summer Road, LLC: Research Funding; Formation Biologics: Research Funding. Hoffman:Incyte: Research Funding; Summer Road: Research Funding; Merus: Research Funding; Janssen: Research Funding; Formation Biologics: Research Funding." @default.
• W2912605890 created "2019-02-21" @default.
• W2912605890 creator A5006372952 @default.
• W2912605890 creator A5015365039 @default.
• W2912605890 creator A5026108947 @default.
• W2912605890 creator A5058644101 @default.
• W2912605890 creator A5060907157 @default.
• W2912605890 creator A5066827889 @default.
• W2912605890 creator A5072336042 @default.
• W2912605890 creator A5075549153 @default.
• W2912605890 date "2018-11-29" @default.
• W2912605890 modified "2023-10-18" @default.
• W2912605890 title "AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β1 Signaling in Human Myelofibrosis" @default.
• W2912605890 doi "https://doi.org/10.1182/blood-2018-99-116474" @default.
• W2912605890 hasPublicationYear "2018" @default.
• W2912605890 type Work @default.
• W2912605890 sameAs 2912605890 @default.
• W2912605890 citedByCount "16" @default.
• W2912605890 countsByYear W29126058902019 @default.
• W2912605890 countsByYear W29126058902020 @default.
• W2912605890 countsByYear W29126058902021 @default.
• W2912605890 countsByYear W29126058902022 @default.
• W2912605890 countsByYear W29126058902023 @default.
• W2912605890 crossrefType "journal-article" @default.
• W2912605890 hasAuthorship W2912605890A5006372952 @default.
• W2912605890 hasAuthorship W2912605890A5015365039 @default.
• W2912605890 hasAuthorship W2912605890A5026108947 @default.
• W2912605890 hasAuthorship W2912605890A5058644101 @default.
• W2912605890 hasAuthorship W2912605890A5060907157 @default.
• W2912605890 hasAuthorship W2912605890A5066827889 @default.
• W2912605890 hasAuthorship W2912605890A5072336042 @default.
• W2912605890 hasAuthorship W2912605890A5075549153 @default.
• W2912605890 hasBestOaLocation W29126058901 @default.
• W2912605890 hasConcept C109159458 @default.
• W2912605890 hasConcept C118131993 @default.
• W2912605890 hasConcept C134018914 @default.
• W2912605890 hasConcept C185592680 @default.
• W2912605890 hasConcept C203014093 @default.
• W2912605890 hasConcept C2776112149 @default.
• W2912605890 hasConcept C2777863708 @default.
• W2912605890 hasConcept C2779705218 @default.
• W2912605890 hasConcept C2780007613 @default.
• W2912605890 hasConcept C2780076729 @default.
• W2912605890 hasConcept C28328180 @default.
• W2912605890 hasConcept C502942594 @default.
• W2912605890 hasConcept C71924100 @default.
• W2912605890 hasConcept C86803240 @default.
• W2912605890 hasConcept C95444343 @default.
• W2912605890 hasConceptScore W2912605890C109159458 @default.
• W2912605890 hasConceptScore W2912605890C118131993 @default.
• W2912605890 hasConceptScore W2912605890C134018914 @default.
• W2912605890 hasConceptScore W2912605890C185592680 @default.
• W2912605890 hasConceptScore W2912605890C203014093 @default.
• W2912605890 hasConceptScore W2912605890C2776112149 @default.
• W2912605890 hasConceptScore W2912605890C2777863708 @default.
• W2912605890 hasConceptScore W2912605890C2779705218 @default.
• W2912605890 hasConceptScore W2912605890C2780007613 @default.
• W2912605890 hasConceptScore W2912605890C2780076729 @default.
• W2912605890 hasConceptScore W2912605890C28328180 @default.
• W2912605890 hasConceptScore W2912605890C502942594 @default.
• W2912605890 hasConceptScore W2912605890C71924100 @default.
• W2912605890 hasConceptScore W2912605890C86803240 @default.
• W2912605890 hasConceptScore W2912605890C95444343 @default.
• W2912605890 hasIssue "Supplement 1" @default.
• W2912605890 hasLocation W29126058901 @default.
• W2912605890 hasOpenAccess W2912605890 @default.
• W2912605890 hasPrimaryLocation W29126058901 @default.
• W2912605890 hasRelatedWork W1745876821 @default.
• W2912605890 hasRelatedWork W2009654620 @default.
• W2912605890 hasRelatedWork W2047949563 @default.
• W2912605890 hasRelatedWork W2108585990 @default.
• W2912605890 hasRelatedWork W2116774122 @default.
• W2912605890 hasRelatedWork W2124941143 @default.
• W2912605890 hasRelatedWork W2767173620 @default.
• W2912605890 hasRelatedWork W2795808866 @default.
• W2912605890 hasRelatedWork W3103959747 @default.
• W2912605890 hasRelatedWork W3182217228 @default.
• W2912605890 hasVolume "132" @default.
• W2912605890 isParatext "false" @default.
• W2912605890 isRetracted "false" @default.
• W2912605890 magId "2912605890" @default.
• W2912605890 workType "article" @default.